Eli Lilly Likely to Post Strong Volume Growth in Q3, RBC Says

MT Newswires Live10-12 23:32

Eli Lilly (LLY) is likely to post a strong volume growth in Q3 that is expected to outweigh pricing headwinds, RBC Capital Markets said in a Monday note. The Q3 results are due Oct. 29.

RBC analysts said they are about 2% above consensus on sales, driven by Zepbound and Mounjaro, partially offset by modest pricing pressure, and weaker ex-GLP-1 sales. They expect Q3 EPS of $6.34 on revenue of $22.95 billion.

A recent sell-down of the shares on Bridge Program pricing concerns was overdone as Bridge now represents only about 10% of US total prescriptions, the report said.

The analysts also said they expect an increase of some $2 billion in guidance on the back of continued incretin momentum in the quarter, in line with increases in Q1 and Q2.

RBC kept its outperform rating and price target of $1,500.

Price: 1183.36, Change: +4.09, Percent Change: +0.35

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment